DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 93 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactCompany

BALAXI PHARMACEUTICALS LIMITED — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 52 min ago·7 Oct 2026, 9:06 am

Balaxi Pharmaceuticals

Balaxi Pharmaceuticals Limited has informed stock exchanges that it has received a certificate under SEBI's Depositories and Participants Regulations, 2018. This regulatory filing confirms that the company has successfully complied with the requirements for maintaining its securities in electronic form.

For investors, this news is largely procedural and confirms that the company's shareholding structure is properly documented and compliant with market regulations. It does not indicate any operational changes or financial performance updates.

Investors should monitor the company's future quarterly results to gauge its business performance, as this regulatory update does not itself impact the stock's price.